3 Drugs Stocks On The Rise

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 69 points (-0.4%) at 16,384 as of Monday, March 10, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 999 issues advancing vs. 1,928 declining with 160 unchanged.

The Drugs industry currently sits down 0.1% versus the S&P 500, which is down 0.3%. On the negative front, top decliners within the industry include Incyte ( INCY), down 2.5%, Novo Nordisk A/S ( NVO), down 1.4%, Vertex Pharmaceuticals ( VRTX), down 1.4%, Valeant Pharmaceuticals International ( VRX), down 1.0% and Shire ( SHPG), down 0.9%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3. Teva Pharmaceutical Industries ( TEVA) is one of the companies pushing the Drugs industry higher today. As of noon trading, Teva Pharmaceutical Industries is up $0.61 (1.2%) to $49.91 on average volume. Thus far, 2.7 million shares of Teva Pharmaceutical Industries exchanged hands as compared to its average daily volume of 6.7 million shares. The stock has ranged in price between $49.09-$49.92 after having opened the day at $49.71 as compared to the previous trading day's close of $49.30.

Teva Pharmaceutical Industries Limited, together with its subsidiaries, develops, manufactures, sells, and distributes pharmaceutical products worldwide. The company offers generic pharmaceutical products; and basic chemicals, as well as specialized product families. Teva Pharmaceutical Industries has a market cap of $47.2 billion and is part of the health care sector. Shares are up 24.3% year-to-date as of the close of trading on Friday. Currently there are 6 analysts who rate Teva Pharmaceutical Industries a buy, 3 analysts rate it a sell, and 9 rate it a hold.

TheStreet Ratings rates Teva Pharmaceutical Industries as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, increase in net income, expanding profit margins, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Teva Pharmaceutical Industries Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

S&P 500 and Dow Score Records With Wall Street Upbeat Ahead of Fed

S&P 500 and Dow on Track for Records With Markets in Good Mood Ahead of Fed

S&P 500 and Dow Aim for New Records With Broad-Based Gains Ahead of Fed

Dow and S&P 500 Reach New Intraday Highs With Markets in Good Mood Ahead of Fed

Teva's New CEO Brings This Secret Weapon